Literature DB >> 28495044

Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: A longitudinal follow-up.

Gail A Spiridigliozzi1, Lori A Keeling2, Mihaela Stefanescu3, Cindy Li4, Stephanie Austin5, Priya S Kishnani6.   

Abstract

This study examines the long-term cognitive and academic outcomes of 11 individuals with infantile onset Pompe disease (IOPD) (median age=11years, 1month, range=5years, 6months through 17years of age) treated with enzyme replacement therapy from an early age. All participants (7 males, 4 females) were administered individual intelligence tests (Wechsler or Leiter scales or both), a measure of their academic skill levels (Woodcock-Johnson Tests of Achievement), and a screening measure of visual-motor integration ability (Beery-Buktenica). Consistent with our earlier findings, median IQ scores for the entire group on the Wechsler (median=84) and Leiter (median=92) scales continue to fall at the lower end of the average range compared to same-aged peers. The median scores for the group on a measure of visual-motor integration (median=76), visual perception (median=74) and motor coordination (median=60) were below average. Two distinct subgroups emerged based on participants' average or below average performance on the majority of academic subtests. Those participants with below average academic skills (n=6) demonstrated average nonverbal cognitive abilities on the Leiter, but had weaknesses in speech and language skills and greater medical involvement. Their profiles were more consistent with a learning disability diagnosis than an intellectual disability. Two of these participants showed a significant decline (15 and 23 points, respectively) on repeated Wechsler scales, but one continued to earn average scores on the Leiter scales where the verbal and motor demands are minimal. Participants with average academic skills (n=5) demonstrated average cognitive abilities (verbal and nonverbal) on the Wechsler scales and less medical involvement. Their speech and language skills appeared to be more intact. However, both groups earned below average median scores on the Beery-Buktenica motor coordination task. This study highlights the importance of using appropriate tests to capture both verbal and nonverbal abilities, considering each individual's motor skills, speech and language abilities, hearing status and native language. This will allow for a more accurate assessment of whether there is a learning disability or an intellectual disability. Long-term outcomes may be related to the stability of an individual's expressive and/or receptive language abilities over time. Changes in the speech and language domain may account for the decline in IQ observed in some IOPD long-term survivors, reflecting a learning disability rather than a decline in overall cognition or an intellectual disability. These observations, in conjunction with neuroimaging, will further our understanding of the neurocognitive profile of long-term IOPD survivors.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Academic; Cognitive; Infantile-onset Pompe; Visual-motor integration

Mesh:

Substances:

Year:  2017        PMID: 28495044      PMCID: PMC5985833          DOI: 10.1016/j.ymgme.2017.04.014

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  16 in total

1.  Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.

Authors:  B J Ebbink; F K Aarsen; C M van Gelder; J M P van den Hout; N Weisglas-Kuperus; J Jaeken; M H Lequin; W F M Arts; A T van der Ploeg
Journal:  Neurology       Date:  2012-04-25       Impact factor: 9.910

Review 2.  White matter in learning, cognition and psychiatric disorders.

Authors:  R Douglas Fields
Journal:  Trends Neurosci       Date:  2008-06-05       Impact factor: 13.837

Review 3.  Inborn errors of metabolism: combining clinical and radiologic clues to solve the mystery.

Authors:  Mohannad Ibrahim; Hemant A Parmar; Nickoleta Hoefling; Ashok Srinivasan
Journal:  AJR Am J Roentgenol       Date:  2014-09       Impact factor: 3.959

4.  Early cognitive development in children with infantile Pompe disease.

Authors:  Gail A Spiridigliozzi; James H Heller; Laura E Case; Harrison N Jones; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2011-10-28       Impact factor: 4.797

5.  Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Shinn-Forng Peng; Wuh-Liang Hwu
Journal:  Pediatr Res       Date:  2006-07-20       Impact factor: 3.756

6.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

Authors:  P S Kishnani; D Corzo; M Nicolino; B Byrne; H Mandel; W L Hwu; N Leslie; J Levine; C Spencer; M McDonald; J Li; J Dumontier; M Halberthal; Y H Chien; R Hopkin; S Vijayaraghavan; D Gruskin; D Bartholomew; A van der Ploeg; J P Clancy; R Parini; G Morin; M Beck; G S De la Gastine; M Jokic; B Thurberg; S Richards; D Bali; M Davison; M A Worden; Y T Chen; J E Wraith
Journal:  Neurology       Date:  2006-12-06       Impact factor: 9.910

7.  Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Chun-An Chen; Fuu-Jen Tsai; Wen-Hui Tsai; Jeng-Yi Shieh; Hsiang-Ju Huang; Wei-Chung Hsu; Tzu-Hsun Tsai; Wuh-Liang Hwu
Journal:  J Pediatr       Date:  2014-11-04       Impact factor: 4.406

8.  Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up.

Authors:  Gail A Spiridigliozzi; James H Heller; Priya S Kishnani
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-01-17       Impact factor: 3.908

Review 9.  Imaging manifestations of the leukodystrophies, inherited disorders of white matter.

Authors:  Edward Yang; Sanjay P Prabhu
Journal:  Radiol Clin North Am       Date:  2014-03       Impact factor: 2.303

10.  Cognitive Development in Infantile-Onset Pompe Disease Under Very Early Enzyme Replacement Therapy.

Authors:  Chih-Jou Lai; Ting-Rong Hsu; Chia-Feng Yang; Shyi-Jou Chen; Ya-Chin Chuang; Dau-Ming Niu
Journal:  J Child Neurol       Date:  2016-09-21       Impact factor: 1.987

View more
  9 in total

Review 1.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

2.  Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy.

Authors:  Paul T McIntosh; Lisa D Hobson-Webb; Zoheb B Kazi; Sean N Prater; Suhrad G Banugaria; Stephanie Austin; Raymond Wang; David S Enterline; Donald P Frush; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-10-13       Impact factor: 4.797

3.  Novel approaches to quantify CNS involvement in children with Pompe disease.

Authors:  Aditi Korlimarla; Gail A Spiridigliozzi; Kelly Crisp; Mrudu Herbert; Steven Chen; Michael Malinzak; Mihaela Stefanescu; Stephanie L Austin; Heidi Cope; Kanecia Zimmerman; Harrison Jones; James M Provenzale; Priya S Kishnani
Journal:  Neurology       Date:  2020-06-09       Impact factor: 9.910

4.  Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy.

Authors:  Chien-Yu Hsueh; Chii-Yuan Huang; Chia-Feng Yang; Chia-Chen Chang; Wei-Sheng Lin; Hsiu-Lien Cheng; Shang-Liang Wu; Yen-Fu Cheng; Dau-Ming Niu
Journal:  Orphanet J Rare Dis       Date:  2021-08-05       Impact factor: 4.123

Review 5.  A cross-comparison of cognitive ability across 8 genomic disorders.

Authors:  Michael Mortillo; Jennifer G Mulle
Journal:  Curr Opin Genet Dev       Date:  2021-05-31       Impact factor: 4.665

Review 6.  Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

Authors:  Anthony Tucker-Bartley; Jordan Lemme; Andrea Gomez-Morad; Nehal Shah; Miranda Veliu; Frank Birklein; Claudia Storz; Seward Rutkove; David Kronn; Alison M Boyce; Eduard Kraft; Jaymin Upadhyay
Journal:  Neurosci Biobehav Rev       Date:  2021-02-10       Impact factor: 9.052

Review 7.  Neuromuscular Development and Disease: Learning From in vitro and in vivo Models.

Authors:  Zachary Fralish; Ethan M Lotz; Taylor Chavez; Alastair Khodabukus; Nenad Bursac
Journal:  Front Cell Dev Biol       Date:  2021-10-27

Review 8.  Neuronal Cytoskeleton in Intellectual Disability: From Systems Biology and Modeling to Therapeutic Opportunities.

Authors:  Carla Liaci; Mattia Camera; Giovanni Caslini; Simona Rando; Salvatore Contino; Valentino Romano; Giorgio R Merlo
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

9.  Behavioral, social and school functioning in children with Pompe disease.

Authors:  Aditi Korlimarla; Gail A Spiridigliozzi; Mihaela Stefanescu; Stephanie L Austin; Priya S Kishnani
Journal:  Mol Genet Metab Rep       Date:  2020-08-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.